Indexed metadata
A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis
Yannick Allanore, Peter Wung, Christina Soubrane, Corinne Esperet, Frederic Marrache, Raphael Bejuit, Amel Lahmar, Dinesh Khanna, Christopher P Denton
Source record
Source: Crossref
Published: Dec 1, 2020
DOI: 10.1136/annrheumdis-2020-218447
Open original source ↗Evidence graph
No public relationships recorded yet.
Integrity note: This page is a factual metadata record created by deterministic ingestion. It is not a claim that the work moves a mathematical frontier or has been independently verified.